THERAPY DOSSIER · th-a5e0256c582a

Thiamet-G

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 31092134 ↗2019Reported benefit

Upregulated protein O-GlcNAcylation promoted functional and structural recovery of the contused spinal cord injury in rats by Thiamet-G treatment.

RatSpinal cord injuryContusionWistarFemalen = 74 rats total: sham n=22, injured control n=26, Thiamet-G n…After injury

Model: Contusive spinal cord injury

Thiamet-G raised protein O-GlcNAcylation, improved hindlimb locomotor recovery, reduced lesion size and injury severity, and inhibited microglia and macrophage infiltration and caspase-3 mediated apoptosis.

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…